Cargando…
Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes
BACKGROUND: Effective, evidence-based management of type 2 diabetes (T2D) requires the integration of the best available evidence with clinical experience and patient preferences. METHODS: Studies published from 2000 to 2012 evaluating glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dipeptid...
Autor principal: | Tibaldi, Joseph M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961600/ https://www.ncbi.nlm.nih.gov/pubmed/24535623 http://dx.doi.org/10.1007/s12325-014-0100-5 |
Ejemplares similares
-
The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010) -
Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023) -
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
por: Cobble, Michael
Publicado: (2012) -
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz, Stanley, et al.
Publicado: (2010) -
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
por: Khoo, Joan, et al.
Publicado: (2009)